The EU sports nutrition market is worth $6.61 billion in 2026 and growing. Getting a single sports supplement or nutrition product legally on sale in that market requires working through a compliance sequence specific to the EU regulatory environment, and it is materially different from what US brands encounter at home. This guide covers the five compliance questions every US sports nutrition brand must answer before the first unit ships to an EU consumer.

The first question is Novel Food status. Any ingredient in a supplement that lacks a documented history of EU food consumption before May 15, 1997 requires Novel Food authorization under Regulation (EU) 2015/2283, or Catalogue reclassification, before the product can be legally sold in the EU. NMN, for example, required a full EFSA safety dossier before its positive opinion in May 2026. The 34 probiotic strains reclassified in April 2026 are now accessible without a full authorization process, but only for those specific strains. CBD remains under a provisional acceptable daily intake assessment that affects most commercially available doses. The Novel Food question must come first, because if a key ingredient requires authorization, every other compliance step is premature until that question is answered.

The second question is health claims. The EU operates a positive list of permitted health claims under Regulation (EC) 1924/2006, and claims not on the list cannot legally be used on labeling or in EU marketing. US-standard benefit claims, such as immune support, gut health, energy support or recovery, may have no direct equivalent on the EU permitted list, or may be permitted only under specific conditions. Brands that build EU product copy around US claims without checking the EU positive list create compliance problems at the labeling stage that require reformulating copy, not product. The third question is ingredient-level member state restrictions: the EU-wide position for an ingredient may permit market access while a specific member state has a national restriction that prevents sale there. Ashwagandha is the current high-profile example, with a Denmark ban in force, a Netherlands ban intent confirmed and an EU-wide EFSA assessment in progress.

The fourth question is FIC-compliant labeling under Regulation (EU) 1169/2011. Nutrient reference values in the EU differ from US Daily Values, allergen declaration requirements use EU-specific mandatory wording, and language requirements mean label text must be in the official language or languages of each EU member state where the product is sold. A single English label is not sufficient for multi-market EU distribution, so a product sold in Germany, France and Spain needs labels with German, French and Spanish text. The fifth question is packaging compliance under PPWR (Regulation EU 2025/40): packaging documentation must reference the current regulation, void fill requirements must be met, and EPR registration must be in place for each member state where packaged goods are sold. These five questions define the mandatory sequence, and the order matters: Novel Food status before health claims, health claims before labeling, labeling before launch.

• Novel Food status: any ingredient without pre-1997 EU consumption history requires authorization or Catalogue reclassification before market entry, and this is the first question, not the last
• Health claims: the EU permitted claims list (Reg EC 1924/2006) governs all benefit claims, and US-standard claims may not have direct EU equivalents
• Member state ingredient restrictions: EU-wide clearance does not override national restrictions, such as the Denmark ashwagandha ban and Netherlands ban intent, so check market by market
• FIC labeling: EU nutrient reference values, allergen declaration wording and language requirements differ from US FDA formats, so separate label versions are required for each target member state
• PPWR packaging: void fill compliance, PFAS-free materials and EPR registration in each member state where goods are sold, required before the first unit ships

Each of the five questions has a definite answer: either the ingredient is authorized, the claim is on the permitted list, the labeling is correct, or it is not. None of them requires speculation, only systematic assessment against EU requirements before product decisions are finalized. Expandly's EU market entry program for sports nutrition brands covers all five questions as a pre-launch program, structured to run in parallel with the operational setup for EU fulfillment and marketplace listing, so compliance readiness and operational readiness arrive together.